{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:36:46Z","timestamp":1793363806200,"version":"4.5.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100018096","name":"The GOG Foundation Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018096","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002956","name":"Foundation for Women's Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002956","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ygyno.2026.07.015","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T12:06:47Z","timestamp":1784635607000},"page":"9-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Understanding and addressing enrollment gaps and opportunities in gynecologic oncology clinical trials: A scoping review"],"prefix":"10.1016","volume":"212","author":[{"given":"Teresa K.L.","family":"Boitano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn G.","family":"Dinkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Fennell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"McKenzie","family":"Foxall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Purva","family":"Pawar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Charles A.","family":"Leath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warner K.","family":"Huh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca C.","family":"Arend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ygyno.2026.07.015_bb0005","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/1471-0528.14528","article-title":"Participation in clinical trials improves outcomes in women\u2019s health: a systematic review and meta-analysis","volume":"124","author":"Nijjar","year":"2017","journal-title":"BJOG"},{"issue":"3","key":"10.1016\/j.ygyno.2026.07.015_bb0010","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/AOG.0000000000005298","article-title":"Association of clinical trial participation with improved overall survival for recurrent, platinum-resistant ovarian cancer","volume":"142","author":"Morton","year":"2023","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2026.07.015_bb0015","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1591000","article-title":"Impact of clinical trial participation on the survival of patients with newly diagnosed advanced ovarian cancer","volume":"15","author":"Lee","year":"2025","journal-title":"Front. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2026.07.015_bb0020","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.38648","article-title":"Trial enrollment and survival disparities among patients with advanced epithelial ovarian carcinoma","volume":"8","author":"Johnson","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ygyno.2026.07.015_bb0025","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ygyno.2025.07.029","article-title":"Health equity, disparities, and barriers to cervical cancer care in the U.S.: a consensus statement by SGO, ACOG, ASCCP, ASTRO, and ABS","volume":"200","author":"Neibart","year":"2025","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2026.07.015_bb0030","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/jnci\/djaf355","article-title":"Social vulnerability and clinical trial enrollment: the next frontier of health equity","volume":"118","author":"Perati","year":"2026","journal-title":"J. Natl. Cancer Inst."},{"issue":"3","key":"10.1016\/j.ygyno.2026.07.015_bb0035","first-page":"287","article-title":"Disparities in gynecologic cancer incidence, treatment, and survival: a narrative review of outcomes among Black and White women in the United States","volume":"32","author":"Towner","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2026.07.015_bb0040","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-025-13698-2","article-title":"Differences in rural and urban patient perceptions of facilitative factors for cancer clinical trial participation","volume":"25","author":"Lent","year":"2025","journal-title":"BMC Health Serv. Res."},{"issue":"1","key":"10.1016\/j.ygyno.2026.07.015_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2024.100013","article-title":"Trends in the incidence and mutational landscape of advanced uterine cancer","volume":"35","author":"Francoeur","year":"2025","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"4","key":"10.1016\/j.ygyno.2026.07.015_bb0050","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.1235","article-title":"Geographic distribution and survival outcomes for rural patients with cancer treated in clinical trials","volume":"1","author":"Unger","year":"2018","journal-title":"JAMA Netw. Open"},{"issue":"13","key":"10.1016\/j.ygyno.2026.07.015_bb0055","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35944","article-title":"An examination of factors associated with disparities in clinical trial eligibility guided by the socioecological model","volume":"131","author":"Zhao","year":"2025","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2026.07.015_bb0060","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(06)70576-9","article-title":"Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors","volume":"7","author":"Mills","year":"2006","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.07.015_bb0065","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1001\/jamaoncol.2018.5953","article-title":"Association of patient comorbid conditions with cancer clinical trial participation","volume":"5","author":"Unger","year":"2019","journal-title":"JAMA Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.07.015_bb0070","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1177\/1740774520901514","article-title":"Discordant attitudes and beliefs about cancer clinical trial participation between physicians, research staff, and cancer patients","volume":"17","author":"Hillyer","year":"2020","journal-title":"Clin. Trials"},{"key":"10.1016\/j.ygyno.2026.07.015_bb0075","article-title":"Determinants of first-line clinical trial enrollment among Black and White gynecologic cancer patients","author":"Carey","year":"2025","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.ygyno.2026.07.015_bb0080","article-title":"Improved clinical trial race\/ethnicity reporting and updated inclusion profile, 2017-2022: a New Jersey snapshot","volume":"7","author":"Paleoudis","year":"2023","journal-title":"Glob. Epidemiol."},{"issue":"11","key":"10.1016\/j.ygyno.2026.07.015_bb0085","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1136\/ijgc-2021-002557","article-title":"Not immune to inequity: minority under-representation in immunotherapy trials for breast and gynecologic cancers","volume":"31","author":"Grette","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2026.07.015_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2023.12.001","article-title":"Underrepresentation of racial and ethnic minority groups in gynecologic oncology: an analysis of over 250 trials","volume":"181","author":"Richardson","year":"2024","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2026.07.015_bb0095","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1097\/AOG.0000000000004917","article-title":"Enrollment of individuals from racial and ethnic minority groups in Gynecologic Cancer precision oncology trials","volume":"140","author":"Mattei","year":"2022","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2026.07.015_bb0100","first-page":"67","article-title":"A systematic review of ethnic minority participation in randomised controlled trials of systemic therapies for gynecological cancers","volume":"183","author":"Steventon","year":"2024","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.07.015_bb0105","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ygyno.2016.06.015","article-title":"Patient perceptions and willingness to participate in clinical trials","volume":"142","author":"Igwe","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.07.015_bb0110","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jrh.12492","article-title":"Factors predicting participation in the prospective genomic sequencing study, Total Cancer care (TCC), in Kentucky","volume":"38","author":"Riggs","year":"2022","journal-title":"J. Rural Health"},{"issue":"7","key":"10.1016\/j.ygyno.2026.07.015_bb0115","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1111\/IGC.0b013e3181b33ace","article-title":"Retrospective analysis of concomitant cisplatin during radiation in patients aged 55 years or older for treatment of advanced cervical cancer: a gynecologic oncology group study","volume":"19","author":"Kunos","year":"2009","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2026.07.015_bb0120","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ygyno.2024.08.007","article-title":"The role of race\/ethnicity and age in clinical trial knowledge among patients with gynecologic malignancy","volume":"190","author":"Guerra","year":"2024","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.07.015_bb0125","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.ygyno.2020.03.002","article-title":"Minority participation in phase 1 gynecologic oncology clinical trials: three decades of inequity","volume":"157","author":"Awad","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.07.015_bb0130","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ygyno.2024.11.003","article-title":"Clinical trial enrollment during first course of gynecologic cancer treatment and survival","volume":"192","author":"Khadraoui","year":"2025","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.07.015_bb0135","first-page":"109","article-title":"Minority participation in Gynecologic oncology group (GOG) studies","volume":"138","author":"Scalici","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2026.07.015_bb0140","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.46494","article-title":"Racial and ethnic disparities in clinical trial enrollment among women with gynecologic cancer","volume":"6","author":"Khadraoui","year":"2023","journal-title":"JAMA Netw. Open"},{"issue":"1","key":"10.1016\/j.ygyno.2026.07.015_bb0145","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/GRF.0000000000000765","article-title":"Enrollment of racial and ethnic minoritized groups in Gynecologic oncology clinical trials: a review of the scope of the problem, contributing factors, and strategies to improve inclusion","volume":"66","author":"Barry","year":"2023","journal-title":"Clin. Obstet. Gynecol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.07.015_bb0150","doi-asserted-by":"crossref","first-page":"110.e1","DOI":"10.1016\/j.ajog.2025.01.026","article-title":"Racial and ethnic enrollment disparities in clinical trials leading to Food and Drug Administration approvals for gynecologic malignancies","volume":"233","author":"Levin","year":"2025","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"8","key":"10.1016\/j.ygyno.2026.07.015_bb0155","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/COC.0000000000001107","article-title":"Racial disparities in endometrial Cancer clinical trial representation: exploring the role of eligibility criteria","volume":"47","author":"Wolf","year":"2024","journal-title":"Am. J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2026.07.015_bb0160","doi-asserted-by":"crossref","first-page":"379.e1","DOI":"10.1016\/j.ajog.2024.09.103","article-title":"Disparities in clinical drug trial participation in endometrial cancer: a real-world analysis","volume":"232","author":"Smith","year":"2025","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2026.07.015_bb0165","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ygyno.2023.05.066","article-title":"Disparities in clinical trial participation in ovarian cancer: a real-world analysis","volume":"175","author":"Smith","year":"2023","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.07.015_bb0170","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ygyno.2022.01.032","article-title":"Racial and ethnic enrollment disparities in clinical trials of poly(ADP-ribose) polymerase inhibitors for gynecologic cancers","volume":"165","author":"Wagar","year":"2022","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.07.015_bb0175","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ygyno.2016.09.026","article-title":"The generalizability of NCI-sponsored clinical trials accrual among women with gynecologic malignancies","volume":"143","author":"Mishkin","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.07.015_bb0180","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.ygyno.2021.11.013","article-title":"Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: an NRG oncology\/gynecologic oncology group study","volume":"164","author":"duPont","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.07.015_bb0185","article-title":"Improving clinical trial enrollment in minority racial and ethnic patients with gynecologic malignancy","volume":"55","author":"Lara","year":"2024","journal-title":"Gynecol. Oncol. Rep."},{"issue":"1","key":"10.1016\/j.ygyno.2026.07.015_bb0190","doi-asserted-by":"crossref","first-page":"27","DOI":"10.6004\/jnccn.2022.7068","article-title":"Participation of patients with limited English proficiency in Gynecologic oncology clinical trials","volume":"21","author":"Jorge","year":"2023","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"6","key":"10.1016\/j.ygyno.2026.07.015_bb0195","first-page":"678.e1","article-title":"Demographic reporting and language exclusion in gynecologic oncology clinical trials","volume":"229","author":"Lee","year":"2023","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.07.015_bb0200","article-title":"Perspectives on inclusion, diversity, equity, and access in clinical trials: findings from a 6-continent survey","volume":"35","author":"Dimitrova","year":"2025","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2026.07.015_bb0205","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ygyno.2023.11.025","article-title":"An absence of translated consent forms limits oncologic clinical trial enrollment for limited English proficiency participants","volume":"180","author":"Guo","year":"2024","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2026.07.015_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.101927","article-title":"Unnecessary exclusions: eligibility criteria in gynecologic oncology interventional clinical trials impairs access","volume":"36","author":"Holtzman","year":"2026","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2026.07.015_bb0215","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/IGJ.0b013e31819a1ce8","article-title":"Clinical trial participation is associated with improved outcome in women with ovarian cancer","volume":"19","author":"Robinson","year":"2009","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2026.07.015_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2024.100066","article-title":"Dedicated research navigators: a tool to decrease disparities in clinical trial enrollment?","volume":"35","author":"Boitano","year":"2025","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2026.07.015_bb0225","article-title":"Developing a manual clinical trials screening process in a diverse southern gynecologic oncology practice","volume":"57","author":"Klein","year":"2024","journal-title":"Gynecol. Oncol. Rep."},{"issue":"3","key":"10.1016\/j.ygyno.2026.07.015_bb0230","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ygyno.2009.12.005","article-title":"Addressing clinical trials: can the multidisciplinary tumor board improve participation? A study from an academic women\u2019s cancer program","volume":"116","author":"Kuroki","year":"2010","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.07.015_bb0235","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ygyno.2015.05.008","article-title":"A novel clinical trial recruitment strategy for women\u2019s cancer","volume":"138","author":"Rimel","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.07.015_bb0240","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ygyno.2020.01.040","article-title":"Are ethnic and racial minority women less likely to participate in clinical trials?","volume":"157","author":"Patel","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.07.015_bb0245","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ygyno.2011.02.007","article-title":"Recruitment and retention results for a population-based cervical cancer biobehavioral clinical trial","volume":"121","author":"Osann","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.07.015_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2024.101379","article-title":"Screening log: challenges in community patient recruitment for gynecologic oncology clinical trials","volume":"42","author":"Ratnaparkhi","year":"2024","journal-title":"Contemp Clin. Trials Commun."},{"issue":"9","key":"10.1016\/j.ygyno.2026.07.015_bb0255","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003758","article-title":"Evaluating the frequency of English language requirements in clinical trial eligibility criteria: a systematic analysis using ClinicalTrials.gov","volume":"18","author":"Muthukumar","year":"2021","journal-title":"PLoS Med."},{"issue":"7975","key":"10.1016\/j.ygyno.2026.07.015_bb0260","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/s41586-023-06382-0","article-title":"Consent document translation expense hinders inclusive clinical trial enrolment","volume":"620","author":"Velez","year":"2023","journal-title":"Nature"},{"issue":"Suppl. 16","key":"10.1016\/j.ygyno.2026.07.015_bb0265","article-title":"Identifying physician perspectives of facilitators and barriers in clinical trial accrual to inform implementation strategies for advancing equitable enrollment in a large comprehensive cancer center","volume":"43","author":"Gill","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 16","key":"10.1016\/j.ygyno.2026.07.015_bb0270","article-title":"Challenges and solutions to recruiting diverse populations to oncology clinical trials: a mixed-methods study of clinical research coordinators","volume":"42","author":"Manana","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.07.015_bb0275","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ygyno.2024.01.031","article-title":"Critical decisions: a mixed-methods study of decision-making among diverse gynecologic cancer patients considering therapeutic clinical trial enrollment","volume":"184","author":"Rieder","year":"2024","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.07.015_bb0280","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ygyno.2015.04.033","article-title":"Patient and physician factors associated with participation in cervical and uterine cancer trials: an NRG\/GOG247 study","volume":"138","author":"Brooks","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"22","key":"10.1016\/j.ygyno.2026.07.015_bb0285","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1002\/cncr.34455","article-title":"Associations between geography, decision-making style, and interest in cancer clinical trial participation","volume":"128","author":"Caston","year":"2022","journal-title":"Cancer"},{"issue":"21","key":"10.1016\/j.ygyno.2026.07.015_bb0290","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1002\/cncr.34454","article-title":"Interventions to increase racial and ethnic minority accrual into cancer clinical trials: a systematic review","volume":"128","author":"Nouvini","year":"2022","journal-title":"Cancer"},{"issue":"Suppl. 11","key":"10.1016\/j.ygyno.2026.07.015_bb0295","article-title":"Breaking barriers: effective interventions amplifying minority participation in cancer clinical trials","volume":"19","author":"Pottinger","year":"2023","journal-title":"JCO Oncol. Pract."},{"issue":"15","key":"10.1016\/j.ygyno.2026.07.015_bb0300","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.71125","article-title":"Implementation of a patient navigation program to support representative participation in cancer clinical trials","volume":"14","author":"Makhnoon","year":"2025","journal-title":"Cancer Med."},{"issue":"2","key":"10.1016\/j.ygyno.2026.07.015_bb0305","article-title":"Perspectives on GUIDE (guiding participation toward understanding, inclusion, diversity, and equity for cancer trials): a clinical trial access intervention","volume":"37","author":"Karvonen","year":"2026","journal-title":"Cancer Causes Control."},{"issue":"24","key":"10.1016\/j.ygyno.2026.07.015_bb0310","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1001\/jama.2024.6281","article-title":"Survival benefit associated with participation in clinical trials of anticancer drugs: a systematic review and meta-analysis","volume":"331","author":"Iskander","year":"2024","journal-title":"JAMA"},{"issue":"Suppl. 28","key":"10.1016\/j.ygyno.2026.07.015_bb0315","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1200\/JCO.2022.40.28_suppl.093","article-title":"Underrepresented minority clinical trial participation: perspectives of the research care team and patients","volume":"40","author":"Warner","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 16","key":"10.1016\/j.ygyno.2026.07.015_bb0320","article-title":"Using key stakeholder interviews to inform implementation of a cancer center collaborative intervention to improve clinical trial accruals","volume":"41","author":"Goel","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 11","key":"10.1016\/j.ygyno.2026.07.015_bb0325","article-title":"The state of cancer treatment trials in America: a comparison of counties with and without active trials by demography and social vulnerability","volume":"19","author":"Kirkwood","year":"2023","journal-title":"JCO Oncol. Pract."},{"issue":"5","key":"10.1016\/j.ygyno.2026.07.015_bb0330","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/jnci\/djae338","article-title":"Gynecologic cancer clinical trial eligibility criteria as a marker for equitable clinical trial access","volume":"117","author":"Oluloro","year":"2025","journal-title":"J. Natl. Cancer Inst."},{"issue":"11","key":"10.1016\/j.ygyno.2026.07.015_bb0335","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.47635","article-title":"Geographic disparities in gynecologic oncology clinical trial availability in the US","volume":"7","author":"Boland","year":"2024","journal-title":"JAMA Netw. Open"},{"issue":"19","key":"10.1016\/j.ygyno.2026.07.015_bb0340","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1200\/JCO.22.00754","article-title":"Increasing racial and ethnic diversity in cancer clinical trials: an American Society of Clinical Oncology and Association of Community Cancer Centers joint research statement","volume":"40","author":"Oyer","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.07.015_bb0345","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1200\/JOP.19.00256","article-title":"Before consent: qualitative analysis of deliberations of patients with advanced cancer about early-phase clinical trials","volume":"16","author":"Garrett","year":"2020","journal-title":"JCO Oncol. Pract."},{"issue":"2","key":"10.1016\/j.ygyno.2026.07.015_bb0350","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/02692163221137105","article-title":"Motivations and experiences of patients with advanced cancer participating in phase 1 clinical trials: a qualitative study","volume":"37","author":"Yang","year":"2023","journal-title":"Palliat. Med."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826020731?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826020731?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:41:45Z","timestamp":1789692105000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825826020731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":70,"alternative-id":["S0090825826020731"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.07.015","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding and addressing enrollment gaps and opportunities in gynecologic oncology clinical trials: A scoping review","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}